research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
In December 2017, he signed Tax Reform for Acceleration and Inclusion Law (TRAIN Law) which excludes those earning an annual taxable income of ₱250,000 and below from paying the personal income tax, while raising higher excise taxes on vehicles, sugar-sweetened beverages, petroleum products, tobacco and other non-essential goods. Revenues collected from the TRAIN law will help fund the administration's massive infrastructure program. In March 2021, to attract more investments and maintain fiscal stability, Duterte signed the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act, reducing the 30 percent corporate income tax rate to 25 percent for firms with assets above ₱100 million and to 20 percent for smaller firms. Duterte raised sin taxes on tobacco and vapor products in July 2019, and alcohol beverages and electronic cigarettes in January 2020, to fund the Universal Health Care Act and reduce incidence of deaths and diseases associated with smoking and alcohol consumption. Duterte's tax reform program has garnered both support and criticism. Critics have argued that the administration's tax policy would burden the poor. The implementation of the TRAIN Law triggered protests from various left-wing groups. On January 15, 2018, protesters gathered at various public market sites, calling for the revocation of TRAIN. However, proponents of the program cite its appeal to foreign investors and economic benefits as the main reasons behind tax reform.
From Taxco, the party traveled through mountainous terrain to Cuernavaca and then to a vantage point above the Valley of Mexico, where Humboldt admired the lakes, ancient ruins, and the city of Mexico itself. He regarded Mexico City as a magnificent metropolis, rich in history and architecture, and was warmly received by local society. Humboldt and his party were provided with comfortable lodgings and given official support by the Viceroy, Don Jose de Iturrigaray, who granted them access to archives, mines, plantations, and antiquities. Humboldt found the city’s educational institutions, particularly the School of Mines, to be outstanding in Latin America. He contributed to a geology textbook, which became the first of its kind in the Americas to bear his name as co-author. At the central square of Mexico City, the Zócalo, Humboldt was introduced to ongoing excavations near the imposing Cathedral. He was particularly inspired by the discovery of Aztec sculptures, most notably the famous Aztec calendar stone. Encountering these artifacts firsthand, Humboldt felt a sense of awe at the evidence of sophisticated ancient civilizations. He saw the Aztec calendar as proof of universal human ingenuity, comparing it to the astronomical achievements of Egypt and China. Humboldt meticulously sketched these sculptures, recognizing their value for understanding pre-Columbian history and science. Humboldt, accompanied by Bonpland and the nobleman Carlos de Montúfar, also traveled to the pyramids of Teotihuacan, located northeast of the capital.
For some wine styles, such as light, fruity wines or for low-acid wines from warm climates, malolactic fermentation is not desired. Winemakers can take several steps to prevent MLF from taking place, including:
3-Phosphoglyceric acid (3PG, 3-PGA, or PGA) is the conjugate acid of 3-phosphoglycerate or glycerate 3-phosphate (GP or G3P). This glycerate is a biochemically significant metabolic intermediate in both glycolysis and the Calvin-Benson cycle. The anion is often termed as PGA when referring to the Calvin-Benson cycle. In the Calvin-Benson cycle, 3-phosphoglycerate is typically the product of the spontaneous scission of an unstable 6-carbon intermediate formed upon CO2 fixation. Thus, two equivalents of 3-phosphoglycerate are produced for each molecule of CO2 that is fixed. In glycolysis, 3-phosphoglycerate is an intermediate following the dephosphorylation (reduction) of 1,3-bisphosphoglycerate.
The units use strontium-90, and a larger number of such units have been deployed both on the ground and on the ocean floor than have been used on spacecraft, with public regulatory documents suggesting that the US had deployed at least 100–150 during the 1970s and 1980s. In the past, small "plutonium cells" (very small 238Pu-powered RTGs) were used in implanted heart pacemakers to ensure a very long "battery life". As of 2004, about ninety were still in use. By the end of 2007, the number was reported to be down to just nine. The Mound Laboratory Cardiac Pacemaker program began on 1 June 1966, in conjunction with NUMEC. The program was cancelled in 1972, when it was recognized that the heat source would not remain intact during cremation and there was no way to completely ensure that the units would not be cremated with their users' bodies.
Sources: en.wikipedia.org
== Metabolic diseases == Early studies in the area reported that a liver-derived protein, alpha2-HS Glycoprotein, also known as Fetuin-A, can inhibit insulin tyrosine kinase activation and might play a role in the pathogenesis of metabolic disorders. Results suggest that hepatokine production could remodel metabolic homeostasis. This is exemplified by a number of studies revealing that hepatokines play a pivotal role in metabolism and contribute to the development of obesity, insulin resistance, T2D, NAFL, and NASH (109, 149). So far, ~20 hepatokines have been described to be involved in the regulation of energy and nutrient metabolism by acting directly on the liver or on distal target tissues. Hepatokines can be remodelled depending on the environment, for example, exercise-training can remodel hepatokine secretion. Little work in human hepatokines has been performed, however, using precision-cut liver slicing of human livers with and without MASH over 2000 hepatokines were described with potential roles in either promoting or protecting cardiometabolic disease pathogenesis. Hepatokines are now considered potential targets for the treatment of cardiometabolic disorders.
=== Functioning as signal transducer === Within the last decade, many independent labs have demonstrated that, in addition to the classical ion transporting, this membrane protein can also relay extracellular ouabain-binding signalling into the cell through regulation of protein tyrosine phosphorylation. For instance, a study investigated the function of Na+/K+-ATPase in foot muscle and hepatopancreas in land snail Otala lactea by comparing the active and estivating states. They concluded that reversible phosphorylation can control the same means of coordinating ATP use by this ion pump with the rates of the ATP generation by catabolic pathways in estivating O. lactea. The downstream signals through ouabain-triggered protein phosphorylation events include activation of the mitogen-activated protein kinase (MAPK) signal cascades, mitochondrial reactive oxygen species (ROS) production, as well as activation of phospholipase C (PLC) and inositol triphosphate (IP3) receptor (IP3R) in different intracellular compartments. Protein-protein interactions play a very important role in Na+-K+ pump-mediated signal transduction. For example, the Na+-K+ pump interacts directly with Src, a non-receptor tyrosine kinase, to form a signaling receptor complex. Src is initially inhibited by the Na+-K+ pump. However, upon subsequent ouabain binding, the Src kinase domain is released and then activated. Based on this scenario, NaKtide, a peptide Src inhibitor derived from the Na+-K+ pump, was developed as a functional ouabain–Na+-K+ pump-mediated signal transduction.
==== Esterification ==== HA can be reacted with an epoxide such as glycidyl methacrylate and triethylamine in water to form these ester bonds. Alkyl halides, tosylates, and diazomethane can also be used to create ester bonds, but this reaction requires you to convert the native HA sodium salt to its TBA salt, which can be time consuming. These esterification reactions at the carboxyl group usually require a low pH. There are many different types of esterification reactions at both the carboxyl and hydroxyl groups.
=== Infants === Infantile beriberi usually occurs between two and six months of age in children whose mothers have inadequate thiamine intake. It may present as either wet or dry beriberi. In the acute form, the baby develops dyspnea and cyanosis and soon dies of heart failure. These symptoms may be described in infantile beriberi:
=== Role in parturition === CRH is synthesized by the placenta and seems to determine the duration of pregnancy. Levels rise towards the end of pregnancy just before birth and current theory suggests three roles of CRH in parturition:
Sources: en.wikipedia.org
On 22 September 2014, VESA published the DisplayPort Alternate Mode on USB Type-C Connector Standard, a specification on how to send DisplayPort signals over the newly released USB-C connector. One, two or all four of the differential pairs that USB uses for the SuperSpeed bus can be configured dynamically to be used for DisplayPort lanes. In the first two cases, the connector still can carry a full SuperSpeed signal; in the latter case, at least a non-SuperSpeed signal is available. The DisplayPort AUX channel is also supported over the two sideband signals over the same connection; furthermore, USB Power Delivery according to the newly expanded USB-PD 2.0 specification is possible at the same time. This makes the Type-C connector a strict superset of the use cases envisioned for DockPort, SlimPort, and Mini and Micro DisplayPort. However, DisplayPort Dual-Mode (DP++) is not supported under USB-C alternate mode.
=== Addition of adjuvants === Adjuvants are materials added to improve immunogenicity of recombinant subunit vaccines. Adjuvants increase the magnitude of adaptive response to the vaccine and guide the activation of the most effective forms of immunity for each specific pathogen (e.g. increasing generation of T cell memory). Addition of adjuvants may confer benefits including dose sparing and stabilisation of final vaccine formulation. Appropriate adjuvants are chosen based on safety, tolerance, compatibility of antigen and manufacturing considerations. Commonly used adjuvants for recombinant subunit vaccines are Alum adjuvants (e.g. aluminium hydroxide), Emulsions (e.g. MF59) and Liposomes combined with immunostimulatory molecules (e.g. AS01B).
That same year, Alex B. Novikoff from the University of Vermont visited de Duve's laboratory, and, using electron microscopy, successfully produced the first visual evidence of the lysosome organelle. Using a staining method for acid phosphatase, de Duve and Novikoff further confirmed the location of the hydrolytic enzymes (acid hydrolases) of lysosomes.
The Financial Times reported that "the test showed that China had made astounding progress on hypersonic weapons and was far more advanced than U.S. officials realized." During the Zapad 2021 joint strategic exercise, most of the gear comprised novel Chinese arms such as the KJ-500 airborne early warning and control aircraft, J-20 and J-16 fighters, Y-20 transport planes, and surveillance and combat drones. Another joint forces exercise took place in August 2023 near Alaska. On 24 September 2024, the PLARF performed its first intercontinental ballistic missile (ICBM) test over the Pacific Ocean since the early 1980s.
Haem-using haem peroxidase and the related animal heme-dependent peroxidases DyP-type peroxidase family Catalase Manganese peroxidase some haloperoxidase Di-haem cytochrome c peroxidase Non-heme Thiol: glutathione peroxidase, peroxiredoxin vanadium bromoperoxidase Alkyl hydroperoxide reductase NADH peroxidase
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.